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Objectives This study sought to evaluate the associations between homeostatic indexes of insulin
resistance (HOMA-IR) and post-procedural myocardial injury and clinical outcome after a percutane-
ous coronary intervention (PCI) with a drug-eluting stent.
Background Insulin resistance increases the risk of cardiovascular events. However, the association
between insulin resistance and clinical outcome after coronary intervention is unclear.
Methods We evaluated 516 consecutive patients who underwent elective PCI with drug-eluting
stents. Blood samples were collected from venous blood after overnight fasting, and fasting plasma
glucose and insulin levels were measured. HOMA-IR was calculated according to the homeostasis
model assessment. Post-procedural myocardial injury was evaluated by analysis of troponin T and
creatine kinase-myocardial band isozyme levels hours after PCI. Cardiac event was deﬁned as the
composite endpoint of cardiovascular death, myocardial infarction, and any revascularization.
Results With increasing tertiles of HOMA-IR, post-procedural troponin T and creatine kinase-myo-
cardial band levels increased. In the multiple regression analysis, HOMA-IR was independently asso-
ciated with troponin T elevation. During a median follow-up of 623 days, patients with the highest
tertiles of HOMA-IR had the highest risk of cardiovascular events. The Cox proportional hazard mod-
els identiﬁed HOMA-IR as independently associated with worse clinical outcome after adjustment for
clinical and procedural factors.
Conclusions These results indicated the impact of insulin resistance on post-procedural myocardial
injury and clinical outcome after elective PCI with drug-eluting stent deployment. Evaluation of insu-
lin resistance may provide useful information for predicting clinical outcomes after elective PCI. (J Am
oll Cardiol Intv 2012;5:1159–67) © 2012 by the American College of Cardiology Foundation
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1160Insulin resistance may be a key pathological factor of
metabolic syndrome, and it is associated with risk of type-2
diabetes. Impaired insulin signaling, especially in peripheral
tissues, is associated with abnormal lipid metabolism, hy-
pertension, thrombogenesis, and atherosclerosis, resulting
in increased risk of cardiovascular events (1–5). Several
large-scale cohort studies have documented that insulin
resistance and hyperinsulinemia are associated with in-
creased risk of cardiovascular events (6–8).
See page 1168
Patients who underwent percutaneous coronary interven-
tions (PCI) had a higher risk of recurrent cardiovascular
events (9). In small cohort studies, it was demonstrated that
insulin resistance was associated with neointimal tissue
proliferation of coronary stents and progression of de novo
coronary lesions in patients receiving hemodialysis (10,11).
However, little is known about the impact of insulin
resistance on clinical outcome in
patients who underwent PCI. In
addition, widespread use of
drug-eluting stents (DES) has
revolutionized coronary inter-
ventional practice, and factors
associated with outcome in pa-
tients who underwent PCI may
also change (12,13).
Periprocedural cardiac biomarker
elevation, which was commonly ob-
served after apparent uncomplicated
PCI, is now considered to reflect
post-procedural myocardial injury/
infarction (14). Post-procedural
myocardial injury after PCI was
also associated with worse clinical outcome. Several patient-
related factors, including age, acute coronary syndrome,
inflammatory status, and coronary thrombogenicity, are
associated with post-procedural myocardial injury (14–16).
Several studies have reported that patient-related factors of
post-procedural myocardial injury, such as abnormal lipid
metabolism, thrombogenicity, and systemic inflammation
are also associated with insulin resistance (1,17,18).
Therefore, the aim of this study was to evaluate the
impact of insulin resistance on post-procedural myocardial
injury and long-term clinical outcomes in patients who
underwent elective coronary interventions with DES.
Methods
Study population. A population of 623 consecutive patients
who underwent initial elective PCI with DES in Chubu
Rosai Hospital from January 2006 to October 2008 was
Abbreviations
and Acronyms
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent(s)
HOMA-IR  homeostatic
models of insulin resistance
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TnT  troponin Tenrolled in this study, which was approved by the hospitalethics committee. All patients had angina, documented
myocardial ischemia, or both, and all patients gave their
informed consent for participation in this study. Diabetic
patients treated with any insulin therapy were excluded
because fasting plasma insulin levels, an essential compo-
nent for the calculation of the homeostatic models of insulin
resistance (HOMA-IR), may be affected by insulin therapy.
Patients with elevated pre-procedural troponin levels or who
underwent angioplasty with atherectomy, bare-metal stents,
or balloon angioplasty alone were also excluded. Thus, the
study included 516 patients. Data, including baseline pa-
tient characteristics, procedural characteristics, and clinical
outcomes, were prospectively collected and retrospectively
analyzed.
Evaluation of insulin resistance. Blood samples were col-
ected from venous blood after overnight fasting, and
asting plasma glucose and insulin levels were measured.
OMA-IR was calculated according to the homeostasis
odel assessment as follows: HOMA-IR  fasting insulin
U/ml)  fasting glucose (mg/dl)/405 [or fasting glucose
(mmol/l)/22.5] (19).
Coronary angiography and PCI. All patients underwent
DES implantation with or without pre-dilation. All patients
received treatment with antiplatelet agents for at least 24 h
before the procedure. Furthermore, 5,000 to 10,000 IU of
heparin were administered before stenting, and an addi-
tional bolus of 1,000 to 2,000 IU was given every hour if the
procedure lasted for more than an hour. No patient received
glycoprotein IIb/IIIa receptor inhibitors, which are not
approved for use in Japan. Baseline angiography was eval-
uated by an independent investigator who was not involved
in the procedures and was unaware of the final outcomes. A
computerized quantitative analysis system (QCA-CMS sys-
tem, version 6.0.39.0, MEDIS, Leiden, the Netherlands)
was employed with the guiding catheter for calibration. All
procedures were performed using 6- to 8-F guiding cathe-
ters by either the radial or the femoral approach. The
operator who was blinded to HOMA-IR levels selected the
position and length of the angioplasty and stent implanta-
tion according to angiography and conventional intravascu-
lar ultrasound findings. We administered clopidogrel (75 to
300 mg/day) or ticlopidine (200 mg/day) to prevent throm-
bosis after stent implantation in patients who were not
already receiving thienopyridine derivatives.
Evaluation of cardiac biomarkers. Blood was sampled before
nd 18 h after the procedure. Serum troponin T (TnT) was
easured using an enzyme immunoassay kit (Roche Diag-
ostics, Tokyo, Japan). Creatine kinase-myocardial band
CK-MB) isozyme activity was measured using an immu-
oinhibition assay kit (Sysmex, Kobe, Japan).
Clinical follow-up. Clinical follow-up data were obtained
through in-hospital and outpatient medical records or
telephone interviews until December 2011. The endpoint
was defined as the composite of cardiovascular death,
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1161myocardial infarction (MI), and revascularization, including
target lesion revascularization.
MI was defined as the development of signs and/or
symptoms suggestive of MI, accompanied by elevation of
CK-MB or TnT levels at least 2-fold higher than normal or
new significant Q waves in 2 or more contiguous leads.
After PCI, MI was defined as an elevation of CK-MB or
TnT levels more than 3-fold times the upper limit of normal
or new significant Q waves in at least 2 contiguous leads
(20). Stent thrombosis was defined by Academic Research
Consortium definitions (definite or probably) (21). Target
lesion revascularization was defined as reintervention (percuta-
neous or surgical) for in-stent or in-segment significant steno-
sis (larger than 75% in angiographic diameter stenosis). New
lesion revascularization was defined as revascularization
(percutaneous or surgical) for newly developed significant
lesions that had been nonsignificant (75% in angio-
graphic diameter stenosis) at baseline coronary angiogra-
phy. Ischemia-driven revascularization was defined as
Table 1. Patient Characteristics
Tertile 1
Age, yrs 72.0 9.0
Male 115 (67.3)
Diabetes 78 (45.3)
Hypertension 155 (90.1)
Dyslipidemia 90 (52.3)
Smoking, % 46 (26.7)
Previous myocardial infarction 43 (25.0)
Acute coronary syndrome 35 (20.5)
Body mass index, kg/m2 22.4 3.1
Systolic blood pressure, mm Hg 138.1 25.6
LDL cholesterol, mg/dl 117.5 33.8
HDL cholesterol, mg/dl 51.2 13.3
Triglyceride, mg/dl 109.5 (82.0–165.0)
C-reactive protein, mg/l 1.0 (0.3–0.6)
Hemoglobin A1c, % 6.1 1.16
Estimated GFR, ml/min 62.4 19.1
HOMA-IR 0.90 (0.66–1.11)
Fasting insulin, U/ml 3.6 (2.6–4.6)
Fasting glucose, mg/dl 99.7 21.4
Aspirin 144 (83.7)
Thienopyridine derivative 62 (36.0)
Statins 87 (50.6)
Calcium-channel blocker 76 (44.2)
Beta-blockers 58 (33.7)
ACE inhibitor or ARB 81 (47.1)
Sulfonylurea 33 (19.3)
Metformin 6 (3.5)
Alpha-glucosidase inhibitors 21 (12.3)
Pioglitazone 23 (13.4)
Values are n (%), mean SD (normally distributed data), or median (
ACE angiotensin-converting enzyme; ARB angiotensin II receHOMA-IR homeostatic models of insulin resistance; LDL low-density liprevascularization (percutaneous or surgical) for patients
with evidence of ischemia (ischemic electrocardiographic
change or positive myocardial biomarker) or positive
findings of stress test.
Statistical analysis. All normally distributed data are ex-
pressed as mean  SD. Variables that are not normally
distributed are expressed as median (interquartile range). A
comparison of continuous variables was achieved with the
unpaired Student t test and of categorical variables by using
chi-square analysis or Fisher exact probability test. Com-
parison of cardiac biomarkers (CK-MB and TnT) was
performed using Kruskal-Wallis test and Mann-Whitney U
test. Linear regression analysis and Spearman rank correla-
tion were performed to assess the association between
clinical parameters and increased TnT levels (log-
transformed). Successful normalization of TnT after log-
transformation was evaluated using Kolmogorov-Smirnov
test. To identify predictors of myocardial injury, multiple
regression analyses were performed. Event-free survival was
Tertile 2 Tertile 3 p Value
70.3 8.7 69.7 9.3 0.01
127 (74.7) 117 (68.8) 0.29
89 (51.7) 87 (50.6) 0.45
158 (91.9) 158 (91.9) 0.80
107 (62.2) 101 (58.7) 0.18
34 (19.8) 40 (23.3) 0.31
36 (20.9) 43 (25.0) 0.58
36 (20.9) 37 (21.4) 0.98
23.9 2.9 25.0 3.3 0.01
141.9 21.3 139.4 20.7 0.34
118.9 31.1 120.1 36.2 0.78
45.1 12.9 44.5 11.5 0.01
144.5 (102.0–202.0) 171.8 105.1 0.01
1.0 (0.06–0.35) 8.6 16.6 0.48
6.4 1.41 6.3 1.13 0.16
62.5 24.7 64.3 19.7 0.65
1.78 (1.53–2.07) 3.72 (2.95–5.54) 0.01
6.8 (5.7–7.8) 12.7 (10.3–17.2) 0.01
111.3 23.1 132.4 36.5 0.01
148 (86.0) 147 (85.5) 0.83
77 (44.8) 84 (48.8) 0.05
95 (55.2) 84 (48.8) 0.47
77 (44.8) 63 (36.6) 0.23
71 (41.3) 65 (37.8) 0.35
85 (49.4) 86 (50.0) 0.85
44 (25.6) 47 (27.2) 0.19
12 (7.0) 8 (4.7) 0.32
22 (12.8) 19 (11.0) 0.75
23 (13.4) 15 (8.7) 0.31
artile range) (not normally distributed data).
cker; GFR glomerular filtration rate; HDL high-density lipoprotein;interqu
ptor blooprotein.
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1162analyzed using Kaplan-Meier estimation with the log-rank
test. The Cox proportional hazards model was used to
estimate the contribution of HOMA-IR to the prediction
of cardiovascular events during follow-up periods. In mul-
tivariate analysis, variables listed in Tables 1 or 2 with a
ignificance level 0.1 in the univariate analysis, age, sex,
nd conventional coronary risk factors (hypertension, dia-
etes, body mass index, dyslipidemia, and smoking) were
onsidered candidate variables for inclusion in the multivar-
ate analysis. Post hoc analysis (with Bonferroni correction)
as performed for multiple comparisons. Differences were
onsidered significant at p  0.05. All p values were
derived from 2-sided significance tests.
Figure 1. Post-Procedural TnT and CK-MB Levels in Accordance With the T
Troponin T (TnT) and creatine kinase-myocardial band (CK-MB) isozyme signiﬁcant
[trend]  0.001 and p [trend]  0.018). Post-procedural TnT levels in tertile 3 patients
Table 2. Lesion and Procedural Characteristics
Tertile 1
Target lesions 210
LAD/LCX/RCA/LMT/SVG 85/50/67/8/0
Type B2 or C lesion 118 (56.2)
Reference diameter, mm 2.64 0.22
Minimal lumen diameter, mm 0.83 0.23
Lesion length, mm 17.9 7.93
Sirolimus-eluting stent 215
Paclitaxel-eluting stent 49
Zotarolimus-eluting stent 4
Maximum ballooning pressure, atm 16 (14–20)
Total ballooning time, s 120 (76.3–180
Pre-dilation 152
Post-dilation 137
Values are n, n (%), mean SD (normally distributed data), or media
LAD left anterior descending; LCX left circumflex; LMT leftand tertile 2 patients (0.12  0.26 ng/ml). Post-procedural CK-MB levels in tertile 3 patients (Results
Baseline characteristics. Our population was divided into 3
roups in accordance with tertiles of HOMA-IR at baseline
s follows: 1) tertile 1—HOMA-IR of 1.32 in 172
atients; 2) tertile 2—HOMA-IR of 1.32 to 2.48 in 172
atients; 3) tertile 3—HOMA-IR of2.48 in 172 patients.
linical, angiographic, and procedural parameters of pa-
ients, subdivided according to tertiles of HOMA-IR, are
ummarized in Table 1. There was significant association
etween increased tertiles of HOMA-IR and age, body
ass index, high-density lipoprotein cholesterol, and trig-
ycerides. No difference was observed among the 3 groups in
s of HOMA-IR
eased across tertiles of homeostatic models of insulin resistance (HOMA-IR) (p
0.47 ng/ml) were signiﬁcantly higher than those in tertile 1 (0.11  0.22 ng/ml)
Tertile 2 Tertile 3 p Value
212 212
104/57/48/3/0 95/40/69/6/2 0.15
125 (59.0) 128 (60.4) 0.68
2.64 0.24 2.62 0.26 0.66
0.86 0.30 0.84 0.25 0.48
17.8 7.45 18.1 8.35 0.96
194 212 0.34
37 43 0.45
3 2 0.71
16.5 (14–20) 16 (15–20) 0.65
130 (85–195) 123 (75–168) 0.28
154 145 0.23
132 136 0.75
uartile range) (not normally distributed data).
nk; RCA right coronary artery; SVG saphenous vein graft.ertile
ly incr
(0.26 )
n (interq28.2  39.1 IU/l) were higher than were those in tertile 1 patients (17.6  11.5 IU/l).
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1163lesion characteristics, angiographic parameters, and proce-
dural characteristics.
Post-procedural elevation of TnT and CK-MB. We observed
that post-procedural TnT and CK-MB levels significantly
increased across tertiles of HOMA-IR (p [trend]  0.001
and p [trend]  0.018). Post-procedural TnT levels of
patients in tertile 3 (0.26  0.47 ng/ml) were significantly
higher than those of patients in tertile 1 (0.11  0.22
ng/ml) and tertile 2 (0.12  0.26 ng/ml). Post-procedural
CK-MB levels in tertile 3 patients (28.2  39.1 IU/l) were
higher than those in tertile 1 patients (17.6  11.5 IU/l)
(Fig. 1).
Predictor of post-procedural troponin elevation. The results
f simple and multiple regression analyses with post-
rocedural TnT levels (log-transformed) are given in Table 3.
OMA-IR, total ballooning time, acute coronary syn-
rome, estimated glomerular filtration rate, number of
mplanted stents, female sex, and age were significantly
Figure 2. Kaplan-Meier Curves of Event-Free Survival in Accordance
With HOMA-IR Tertiles
Event-free survival was signiﬁcantly associated with homeostatic models of
insulin resistance (HOMA-IR) tertiles, with worse event-free survival ratios in
tertile 3 patients (67.4%, p  0.001 log-rank test) than in tertile 2 (80.2%)
Table 3. Simple and Multiple-Regression Analysis With Post-Procedural Tn
Variable
Simple Regression
Coefficient (95% CI)
HOMA-IR 0.085 (0.061–0.109)
ACS 0.087 (0.023–0.165)
GFR 0.214 (0.156 to0.273)
Stents, n 0.039 (0.013–0.064)
Female 0.047 (0.006–0.089)
Total ballooning time, s 0.001 (0.000–0.001)
Age 0.002 (0.000–0.004)
ACS acute coronary syndrome; CI confidence interval; TnT troponin T; other abbreviations aand tertile 1 patients (89.5%).ssociated with post-procedural TnT elevation in the simple
egression analysis. HOMA-IR, acute coronary syndrome,
lomerular filtration rate, and number of stents were inde-
endently associated with post-procedural TnT levels in the
ultiple regression analysis after adjusting for age, sex, and
onventional risk factors.
Clinical outcomes. During the median follow-up of 632.8
ays, 28 hard events (cardiac death and nonfatal MI) and
08 total events (hard event and/or any revascularization)
ccurred. Event-free survival was significantly associated with
OMA-IR tertiles, with worse event-free survival ratios in
ertile 3 patients (67.4%; p  0.001, log-rank test) than in
tertile 2 (80.2%) and tertile 1 patients (89.5%) (Fig. 2).
During the follow-up period, coronary angiography was
performed in 33 patients presenting with acute coronary
syndrome and 306 patients with stable symptoms 302  123
days after the procedure. The incidence of emergency angiog-
raphy was significantly increased according to increasing tertile
of HOMA-IR. No difference was found in incidence of
planned angiography among the 3 groups (Table 4).
We observed that the incidence of cardiac death or MI,
target revascularizations, revascularizations for new lesions,
and ischemia-driven revascularization significantly increased
across tertiles of HOMA-IR (p [trend]  0.001, p [trend] 
0.02, p [trend]  0.001, and p [trend]  0.01, respectively).
The incidence of cardiac death or MI, target revascularizations,
revascularizations for new lesions, and ischemia-driven revas-
cularization were significantly higher in tertile 3 patients
than those in tertile 1 and 2 patients were. There was no
significant difference in the incidence of stent thrombosis
among the 3 groups (Fig. 3).
-Transformed)
Multiple Regression
p Value Coefficient (95% CI) p Value
0.001 0.012 (0.005–0.018) 0.001
0.001 0.104 (0.058–0.150) 0.001
0.001 0.002 (0.003 to0.001) 0.001
0.003 0.032 (0.001–0.064) 0.002
0.026 0.035 (0.010–0.075) 0.106
0.004 0.001 (0.001–0.001) 0.112
0.050 0.001 (0.002–0.003) 0.513
le 1.
Table 4. Coronary Angiography During Follow-Up Period
Tertile 1 Tertile 2 Tertile 3 p Value
Emergency CAG 4 (2.3) 12 (7.0) 17 (9.9) 0.01
Planned CAG 100 (58.4) 99 (57.6) 107 (61.9) 0.69
Values are n (%).T (LogCAG coronary angiography.
1I
p
D
. †p 
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1164A Cox proportional hazard models adjusted for age, sex,
and conventional risk factors showed that HOMA-IR
(hazard ratio [HR]: 1.98 per tertile, 95% confidence interval
[CI]: 1.51 to 2.61; p  0.01), number of stents (HR: 1.65,
95% CI: 1.31 to 2.07; p 0.01), total ballooning time (HR:
.00, 95% CI: 1.00-1.00; p  0.01), acute coronary syn-
drome (HR: 2.04, 95% CI: 1.34 to 3.12; p  0.01), and
maximum ballooning pressure (HR: 0.913, 95% CI: 0.85 to
0.93; p  0.01) were independently associated with cardiac
events (Table 5).
Associations were consistent in subgroups, including male
versus female sex (HR per tertile in HOMA-IR: 2.48, 95% CI:
1.75 to 3.52 in men; and HR per tertile in HOMA-IR: 1.18,
95% CI: 0.75 to 1.85 in women), age of 75 years or more versus
age of 75 years, diabetes versus without diabetes, hyperten-
sion versus without hypertension, acute coronary syndrome
versus without acute coronary syndrome, and body mass index
of 25 versus body mass index of 25 kg/m2 (Fig. 4).
ncreasing tertile of HOMA-IR was also an independent
redictor of patient without diabetes.
Figure 3. The Number of Cardiac Events During Follow-Up Period
Increasing tertile of homeostatic models of insulin resistance (HOMA-IR) was signiﬁ
revascularization, revascularization of new lesion, and ischemia-driven revasculariz
respectively).*p  0.01 between patient with tertile 1 or 2 and those with tertile 3
Table 5. Results of Cox Proportional Hazard Model Analysis
Variable
Univariat
HR (95% CI)
HOMA-IR, per tertile 1.887 (1.464–2.433)
Stents, n 1.553 (1.245–1.938)
Total ballooning time, s 1.002 (1.000–1.004)
ACS 1.780 (1.178–2.691)
Maximum ballooning pressure, atm 0.953 (0.920–0.988)
Values are median (interquartile range). This model was adjusted for age and conventional coronarHR hazard ratio; other abbreviations as in Tables 1 and 3.iscussion
The results of this study demonstrated that insulin resis-
tance as estimated by a simple method based on a single
fasting blood sampling is associated with post-procedural
myocardial injury and increases the risk of cardiovascular
events in patients who underwent elective PCI with DES.
These associations were independent after adjustment for
evaluated factors, including age, sex, conventional risk
factors, history of acute coronary syndrome, renal function,
and procedural valuables.
Insulin resistance and post-procedural myocardial injury.
Even in asymptomatic patients without apparent change on
the electrocardiogram, post-procedural elevation of cardiac
biomarkers has been associated with worse clinical out-
comes. Distal embolism following stent expansion may play
an important role in the development of a post-procedural
myocardial injury. Recent studies on distal protection de-
vices confirmed the mobilization of plaque material after
coronary stenting in patients with stable or unstable angina
associated with incidence of death or myocardial infarction (MI), target lesion
p [trend]  0.001, p [trend]  0.02, p [trend]  0.001, and p [trend]  0.01,
0.05 between patient with tertile 1 or 2 and those with tertile 3.
Multivariate
p Value HR (95% CI) p Value
0.001 1.984 (1.510–2.608) 0.001
0.003 1.645 (1.309–2.069) 0.001
0.039 1.003 (1.001–1.005) 0.001
0.006 2.040 (1.335–3.118) 0.001
0.008 0.913 (0.852–0.979) 0.011
ctors (hypertension, diabetes, body mass index, dyslipidemia, and smoking).cantly
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1165(22). Several studies using recently developed imaging
modalities, such as integrated backscatter intravascular ul-
trasound, virtual histology, and multidetector computed
tomography demonstrated that lipid-rich or necrotic char-
acteristics of coronary plaque within target lesion were
strongly associated with post-procedural myocardial injury
(23–25). Additionally, it was reported that coronary lesions
in patients with increased insulin resistance or metabolic
syndrome are associated with more lipid-rich plaque content
(26,27). Therefore, it is plausible that lipid-rich or vulner-
able plaques characteristics of patients with insulin resis-
tance may be associated with post-procedural myocardial
injury and higher risk of cardiovascular events.
Interaction between insulin resistance and other risk factors.
It has been suggested that insulin resistance, as well as
metabolic syndrome, overlaps type-2 diabetes, which is a
known risk factor of cardiac events following PCI and the
clustering of other coronary risk factors. There is a possi-
bility that increased risk of cardiovascular events in patients
with insulin resistance is attributable to overlap with diabe-
tes or other coronary risk factors. However, multivariate
Cox proportional hazards models demonstrated the inde-
pendent association between HOMA-IR and worse clinical
outcome after adjusting for other clinical and procedure-
related factors for cardiac events, including diabetes. In
contrast to previous reports, patients with diabetes in this
study did not have a significantly higher risk of cardiovas-
cular events. There are potential reasons for the relatively
lower event rate for diabetic patients in this study. First, we
Figure 4. Adjusted HR (95% CI) per Tertile of HOMA-IR for Various Subgrou
ACS  acute coronary syndrome; BMI  body mass index; CI  conﬁdence in
resistance.excluded diabetic patients receiving insulin therapy who ohave higher risk of in-stent restenosis and cardiovascular
events than do diabetic patients who were treated with oral
agents because of difficulties in measuring and interpreting
insulin resistance (28). Second, diabetic patients with mul-
tivessel coronary disease or complex lesion characteristics are
subject to referral for bypass surgery, and therefore, diabetic
patients in this study had lower risk than those in other
studies. Third, a relatively small portion of diabetic patients
in this study were treated with insulin-producing drugs
(sulfonylurea, 24%) compared with nonsulfonylurea drugs
(metformin, pioglitazone, and alpha-glucosidase inhibitors,
48%). Beneficial cardiovascular effects of metformin, piogli-
tazone, and alpha-glucosidase inhibitors were demonstrated
in large-scale clinical trials (29–31). Therefore, these med-
ications may contribute to better outcomes in diabetic
patients.
Incidence of stent thrombosis. It has been well documented
hat insulin resistance is associated with increased throm-
ogenicity that results in coronary thrombosis. A recent
eport from other registries suggested that diabetes is an
ndependent predictor of stent thrombosis (32). However,
ecause of the relatively small number of cases of stent
hrombosis in this study, no association between HOMA-IR
ertiles and the rate of stent thrombosis was observed.
he relatively lower incidence of stent thrombosis in this
tudy was comparable to that in the larger DES registry in
apan (33).
Study limitations. Among diabetic patients, antidiabetic
gents could affect fasting insulin levels differently. We
DM  diabetes mellitus; HOMA-IR  the homeostatic models of insulinps
terval;btained post-procedural blood samples only once, at 18 h
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1166after PCI. In daily practice, it may be impractical to
repeatedly collect blood from patients without any apparent
complications. However, 100% of the peak TnT elevations
and 92% of the peak CK-MB levels were observed 12 to
20 h (mean: 17.9  0.46 h) after the procedure in patients
who underwent elective PCI without pre-procedural eleva-
tion of cardiac biomarkers (34). Therefore, we evaluated
cardiac biomarkers obtained from single blood samples at
18 h after PCI.
In this study, the indication for follow-up angiography of
stable patients depends on the attending physician, and
planned follow-up angiography was performed in about
60% of the study population. Even today, 3 to 12 months
after PCI, follow-up angiography is performed in most
stable patients in Japan. There is a concern that follow-up
angiography may lead to unnecessary reinterventions in
asymptomatic patients (35). However, there was no defer-
ence of rate of planned follow-up angiography among each
tertile of patients.
Conclusions
In patients who underwent elective PCI, insulin resistance
calculated by homeostasis model assessment is an indepen-
dent predictor of post-procedural myocardial injury and
cardiovascular events after PCI with DES.
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